

MEDSTAR FAMILY CHOICE FORMULARY UPDATES
April 10, 2026 A d - H o c Pharmacy and Therapeutics Committee Meeting

MedStar Family Choice (MFC) Pharmacy and Therapeutics Committee meets quarterly. During the April 2026 Ad-Hoc meeting, these formulary changes were made. **Bolded** names indicate a brand medication; other listed medications are generic.

UTILIZATION MANAGEMENT: CHANGES EFFECTIVE ON OR AROUND <u>JUNE 1, 2026</u>	
Drug Limitations & Step Therapy	Changes Applied:
Ozempic (<i>semaglutide injection</i>); Ozempic (<i>semaglutide tablet</i>) Rybelsus (<i>semaglutide tablet</i>) Mounjaro (<i>tirzepatide injection</i>)	Managed Drug Limitations; Step Therapy Requirements

*Please see the Prior Authorization and Step Therapy Table for clinical criteria. **The table is updated regularly.** Please use the most current version found on the MFC Providers page: <https://www.medstarfamilychoice.com/maryland-providers/pharmacy-prescription-information>

The MFC P&T Committee welcomes your feedback. Providers can email feedback or requests for formulary changes to: MFC-FormularyFeedback@MedStar.net